

### Synonym

HLA-A\*0201 & B2M & NY-ESO-1 (SLLMWITQV)

### Source

APC-Labeled Human HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein(HL1-HA2H8) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A\*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQV peptide (Accession # [AAA59606.1](#) (HLA-A\*02:01) & [P61769-1](#) (B2M) & SLLMWITQV).

Predicted N-terminus: Gly 25 & Ser

### Molecular Characterization

APC-Labeled Human HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein is assembled by biotinylated monomer and APC-labeled streptavidin.

Biotinylated Human HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. Biotinylated Human HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

### Conjugate

APC

Excitation Wavelength: 640 nm

Emission Wavelength: 661 nm

### Formulation

Lyophilized from 0.22 µm filtered solution in 0.2% BSA with trehalose as protectant.

Contact us for customized product form or formulation.

### Reconstitution

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*

### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

*Please protect from light and avoid repeated freeze-thaw cycles.*

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

### Bioactivity-FACS



5e5 of NY-ESO-1 specific TCR-HEK293 cell line were stained with 100 µL of 1:25 dilution (4 µL stock solution in 100 µL FACS buffer) of APC-Labeled Human HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

## Background

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8<sup>+</sup> T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A\*0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A\*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.

## Clinical and Translational Updates

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.